Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI - BioSpace

Ah, another AI drug discovery press release. It wouldn't be a week in biotech without one. Chai Discovery has graciously licensed its Chai-3 model to Pfizer, presumably so the pharmaceutical giant can generate molecules that look great in silico but fail in phase I trials. The press release from BioSpace touts "accelerated drug discovery," which is corporate speak for "we haven't actually cured anything yet, but here's a nice graph." No financial terms were disclosed — because, as we all know, if the number were impressive, they'd be shouting it from the rooftops.

The Chai-3 model is described as an AI platform for drug discovery, which means it's probably a large language model fine-tuned on PubMed abstracts. Because nothing says "understanding biology" like predicting chemistry from text. Pfizer is no stranger to AI partnerships — they've signed so many that their AI partner portfolio resembles a tech conference attendee list. But have any of these deals delivered a new drug to market? The silence is deafening.

In the end, this license agreement is a masterclass in optics. Chai gets a credibility boost from the Pfizer name, and Pfizer gets to check the "AI innovation" box for another quarterly report. Meanwhile, patients wait for cures, and the PR machine keeps churning. Cheers to progress — perhaps we'll see a drug in 2035 that was started by Chai-3. Until then, pass the popcorn.